EBR Systems (EBR) investor relations material

Novel technology and market opportunity

• WISE CRT System is the world's smallest leadless cardiac pacing device, enabling totally leadless Cardiac Resynchronisation Therapy (CRT) and addressing limitations of traditional CRT systems using wires or leads.

• No direct competitors and is complementary to other pacemaker technologies, protected by over 100 issued patents globally.

• Targets a US total addressable market of $5.8bn, focusing on patients with limited or no other treatment options.

• Premium reimbursement established with a contract price of $63,300, supported by CMS approvals for NTAP, TPT, and TCET programs.

Commercialisation and growth strategy

• Early commercial traction with 41 commercial implants in Q1 2026, more than doubling the previous quarter, and revenue of $2.36m (+150% QoQ).

• 14 new purchase agreements signed in Q1 2026, expanding to major networks like HCA Healthcare, Advocate Health, and CHRISTUS Health.

• 22 additional physicians trained in Q1 2026, bringing the total to 55, supporting future case volume growth.

• New 51,000 sq ft manufacturing facility in Santa Clara to expand capacity, with full transition expected by end of H2 2026.

• Long-term growth strategy includes new indications, product development (e.g., rechargeable battery), and international expansion.

Equity raising and financials

• Fully underwritten equity raise of A$150 million via a two-tranche institutional placement and a 1-for-2 pro-rata accelerated non-renounceable entitlement offer.

• Offer price set at A$0.38 per new CDI, representing a 19.1% discount to last close.

• Proceeds allocated to sales and marketing expansion (44%), manufacturing scale-up (18%), R&D (22%), G&A (11%), and offer costs (6%).

• Q1 2026 revenue reached $2.36m, with 41 commercial implants and a net loss of $17.1m; cash and marketable securities at $30.9m as of March 31, 2026.